Brasco Group Invest 8 Million Euro in Charles Real Estate Joint Venture Deal
22.2.2023 20:34:00 EET | Business Wire | Press release
The Brasco B.V. conglomerate is establishing a joint venture with the real estate company Charles Real Estate.
The Dutch company is thus consolidating its position in the German residential and commercial real estate market.
The Brasco Group continues on its investment tour: with its strategic investment in the joint venture with Charles Real Estate, the Dutch conglomerate is further diversifying its portfolio.
As a first step, the Brasco Group is investing EUR 8 million in the joint venture, and in the course of 2023 is planning to invest a further EUR 30 million.
Charles Real Estate, based in Berlin, has a portfolio of 550 units in Germany with a total lettable space of more than 33,000 square metres. The company's portfolio also includes a property currently under construction with a gross floor area of 16,000 square metres.
Industry insiders regard the investment as proof of the German real estate market's stability. As the coronavirus pandemic appears to have been largely overcome and the energy crisis has been less severe than initially feared, analysts see further growth potential in the German real estate market.
This is already the second investment by the Dutch group to attract attention this year: at the beginning of February, the company announced that it was investing in Mood's Clinic, a well-known manufacturer of medical cannabis.
The Brasco Group is a Dutch conglomerate and parent company of the Brasco group of companies. The Group specialises in trade and logistics, real estate development, financial services – in particular private equity – and the distribution of textiles. The main task of the parent company is to define the strategic orientation of the individual spheres of business and to promote their growth as well as the use of synergies through investment and communication.
The Dutch conglomerate relies on innovative trade concepts to remain competitive in the global and fast-moving circulation of goods and services.
The Group's core competence in the real estate sector is the purchase and management of existing high-end properties in sought-after locations within the Federal Republic of Germany.
The Brasco Group's finance division is responsible for managing and controlling the finances of subsidiaries, suppliers, partners, shareholders and investors. Only employees of the Brasco group of companies are authorised to manage finances, which ensures finances are managed securely.
The investment division of the conglomerate plays a central role in the acquisition of majority stakes: in recent decades, the company has advised on half of all global buyouts with a sales volume of more than $500 million. In addition to buy-out funds, the Brasco Group advises on other types of fund, including hedge funds, real estate funds, private equity funds and infrastructure funds. The Dutch company also advises pension fund, sovereign wealth fund and foundation managers.
More than 1,000 investment experts are associated with the company, and they accompany the investment cycle from the contract negotiation stage to planning the withdrawal.
The Brasco Group intends to float itself on the stock market at the end of 2024.
The Managing Director of the Brasco Group is Rafy Ahmed.
Rafy Ahmed is known to the public from the TV show "Lion's Den". Ahmed founded the fashion brand "Morotai" in 2017 which specialises in sportswear. In 2018, he was awarded the Founder's Prize of the State of Baden-Württemberg. In addition to his work as CEO, he is a lecturer at the International School of Management (ISM) in Stuttgart. As a successful young entrepreneur, he shows students how to start their career. The ISM Stuttgart intends to make the course he teaches an integral part of the "Global Brand & Fashion Management" degree course.
|
Language: |
English |
|
Company: |
Brasco Group |
|
Rivium Boulevard 301 beganegrond en 1e etage |
|
|
2909LK Capelle aan den IJsse |
|
|
Netherlands |
|
|
Internet: |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005788/en/
Contact information
Name: Rafy Ahmed
Tel: +905337840707
Email: info@brascogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom